NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Verastem, Inc. (VSTM) Stock Analysis

Verastem, Inc. (VSTM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VSTM

$8.20

+$0.22 (+2.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VSTM with… →

VSTM Key Statistics

As of Sep 4, 2026
Trading
Open
$7.91
Previous Close
$7.98
Day's Range
7.72–8.21
52-Week Range
3.43–10.82
Volume
2.30M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.32
Valuation
Market Cap
$742.62M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.48
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.44
Financials (FY)
Revenue (FY)
$30.91M+209.14%
Net Income (FY)
−$209.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
−231.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
90.56M
1-Year Return
−22.35%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
2.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VSTM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.22%
2025+49.32%
2024−36.49%
2023+69.58%
2022−80.49%
2021−3.76%
2020+58.96%
2019−60.12%
2018+9.45%
2017+174.11%
2016 (partial year)−15.15%

As of September 4, 2026.

VSTM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$30.91M−$209.47M−677.6%
2024$10.00M−$130.64M−1306.4%
2023$0.00−$87.37M—
2022$2.60M−$73.81M−2843.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$30.91M$25.62M−$170.13M−$209.47M−677.6%
2024$10.00M$10.00M−$114.96M−$130.64M−1306.4%
2023$0.00$0.00−$92.08M−$87.37M—
2022$2.60M$2.60M−$72.94M−$73.81M−2843.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VSTM Valuation vs Biotechnology Median

Median of 656 stocks
MetricVSTMBiotechnology medianvs median
P/S ratio8.4815.2644% below
Profit margin−231.59%0.00%231.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Verastem, Inc. (VSTM) carries a market capitalisation of $742.62M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 102.

The most recent close on file for VSTM is $8.20, dated September 4, 2026. That is +$0.22 (+2.76%) against the previous close. Over the past 52 weeks the price has ranged from $3.43 to $10.82. The latest close sits 139.07% above that 52-week low.

Financial Health

In fiscal 2025, Verastem, Inc. reported revenue of $30.91M. Against the prior fiscal year total of $10.00M, that is a change of +209.14%. The same year closed with a net loss of $209.47M. The reported profit margin is −231.59%. That is 231.6 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −2.44.

Across the 4 fiscal years on file, revenue moves from $2.60M in 2022 to $30.91M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 8.48 times revenue. On price-to-sales that is 44.41% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −22.35%. Measured over 10 years, that is −6.44% a year compounded. The reported beta is 0.32. Daily returns over the trailing 10 years annualize to a volatility of 97.6%.

Growth & Income

No dividend is on file for VSTM.

2026 is still running; the price is +6.22% year to date. The strongest complete calendar year on file is 2017 at +174.11%; the weakest is 2022 at −80.49%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Verastem, Inc. (VSTM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Verastem, Inc. VSTM $742.62M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Verastem, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Verastem, Inc.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Visit website →